前言

英文标题：Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)

中文标题：奥希替尼联合或不联合化疗一线治疗伴TP53共突变的EGFR突变晚期NSCLC（TOP研究）

英文标题：Becotarug (JMT101) and Osimertinib (Osi) in Patients (pts) with Platinum-Pretreated EGFR Exon 20 Insertion-Mutated (ex20ins) Non-Small Cell Lung Cancer (NSCLC): Final Overall Survival (OS) and Subgroup Analyses from the BECOME Phase 2 Study

中文标题：Becotarug (JMT101) 联合奥希替尼治疗既往经含铂化疗的EGFR 20外显子插入突变NSCLC：BECOME II期研究的最终总生存期 (OS) 及亚组分析

英文标题：A first-in-human phase I study of TQB2922, an EGFR/C-MET bispecific antibody, as monotherapy and in combination with bevacizumab and chemotherapy in EGFR-mutant non-small cell lung cancer

中文标题：EGFR/c-MET双特异性抗体TQB2922单药以及联合贝伐珠单抗和化疗治疗EGFR突变NSCLC的首次人体I期研究

英文标题：SHR-A2009, a HER3-targeted ADC, plus aumolertinib (A) as 1L or ≥2L treatment for EGFR-mutated (EGFRm) NSCLC: a phase 1b/2 study

中文标题：HER3靶向ADC药物SHR-A2009联合阿美替尼一线或二线及以上治疗EGFR突变NSCLC：一项Ib/II期研究

英文标题：Comparison of Afatinib and Osimertinib in Advanced or Recurrent Lung Adenocarcinoma with Uncommon EGFR Mutations: TOPGAN2024-01

中文标题：阿法替尼对比奥希替尼治疗伴有EGFR少见突变的晚期或复发性肺腺癌：TOPGAN2024-01研究

英文标题：First-line Subcutaneous Amivantamab Plus Lazertinib in EGFR-mutated Advanced NSCLC: Updated Results From the PALOMA-2 study

中文标题：皮下注射埃万妥单抗联合拉泽替尼一线治疗EGFR突变晚期NSCLC：PALOMA-2研究的更新结果

英文标题：Intracranial (IC) Efficacy of Ivonescimab (Ivo) Plus Chemotherapy (Chemo) in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) in the HARMONi Study

中文标题：HARMONi研究：依沃西单抗联合化疗治疗EGFR TKI耐药的EGFR突变NSCLC的颅内疗效

英文标题：Dacomitinib in advanced NSCLC patients with uncommon EGFR mutations: a multicenter, single-arm, phase II study and biomarker analysis (DANCE study)

中文标题：达可替尼治疗伴有EGFR少见突变的晚期NSCLC患者：一项多中心、单臂、II期研究及生物标志物分析（DANCE研究）

英文标题：Progression-Free Survival and Overall Survival With Pumitamig (PD-L1 _ VEGF-A bsAb) Plus Chemotherapy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer Following Progression With EGFR TKI in China: Phase 2 Study Results

中文标题：Pumitamig（PD-L1/VEGF-A双抗）联合化疗治疗中国EGFR TKI耐药进展后的EGFR突变晚期NSCLC患者的无进展生存期和总生存期：II期研究结果

英文标题：SHR-A2009, a HER3-targeted ADC, plus bevacizumab (Bev) for pretreated EGFR-mutated non-squamous (EGFRm nsq) NSCLC: a phase 1b/2 study

中文标题：HER3靶向ADC药物SHR-A2009联合贝伐珠单抗治疗经治EGFR突变非鳞状NSCLC：一项1b/2期研究

英文标题：Aumolertinib plus oral etoposide (Lastet) as first-line treatment for EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC): The multicenter, phase II EVOLUTION study

中文标题：阿美替尼联合口服依托泊苷一线治疗EGFR突变局部晚期或转移性NSCLC：多中心、II期EVOLUTION研究

英文标题：Capmatinib Combined with EGFR-TKI in EGFR-Mutant Non-Small Cell Lung Cancer with MET Overexpression and Acquired Resistance to Prior EGFR Inhibitors.

中文标题：卡马替尼联合EGFR-TKI治疗伴有MET过表达且对既往EGFR抑制剂产生获得性耐药的EGFR突变NSCLC

英文标题：Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum-pemetrexed (plat-pem) due to progression (PD): FLAURA2 exploratory analysis

中文标题：因疾病进展停用一线奥希替尼联合铂类-培美曲塞治疗的EGFR突变晚期NSCLC患者的化疗再挑战：FLAURA2研究的探索性分析

英文标题：First-line limertinib versus gefitinib in EGFR-mutated advanced NSCLC: Updated overall survival results from a randomized, double-blind, phase 3 trial

中文标题：一线Limertinib对比吉非替尼治疗EGFR突变晚期NSCLC：一项随机、双盲、III期试验的更新总生存期结果